Page 66 - Diamicron MR MIG Cycle 2(20-21) Final

ZACCARDI ET AL. 2421

TABLE 1 Baseline characteristics after high-dimensional propensity score matching
Characteristics Gliclazide MRN = 993 SitagliptinN = 993 Standardized difference
Male (n, %) 583 (58.7%) 593 (59.7%) 0.02049
Age (years) 63.3 (53.4-71.6) 63.1 (54.8-71.5) 0.01847
Diabetes duration (years) 4.4 (2.1-7.3) 4.4 (2.0-7.6) 0.01326
2
Body mass index (kg/m ) 30.8 (27.7-34.8) 31.3 (27.8-35.0) −0.01718
HbA1c (%) 8.5 (7.8-9.7) 8.6 (7.8-9.8) 0.03784
HbA1c (mmol/mol) 69 (62-83) 70 (62-84) —
Practice level IMD (tenths) 0.08857
1 (least deprived) 41 (4.1%) 39 (3.9%)
2 7 (0.7%) 3 (0.3%)
3 63 (6.3%) 64 (6.4%)
4 47 (4.7%) 49 (4.9%)
5 12 (1.2%) 12 (1.2%)
6 37 (3.7%) 45 (4.5%)
7 43 (4.3%) 41 (4.1%)
8 52 (5.2%) 62 (6.2%)
9 78 (7.9%) 73 (7.4%)
10 (most deprived) 43 (4.3%) 38 (3.8%)
Missing 570 (57.4%) 567 (57.1%)
Comorbidities
Previous hypoglycaemia 6 (0.6%) 6 (0.6%) 0.00000
Chronic coronary syndrome 159 (16.0%) 169 (17.0%) 0.02712
Chronic obstructive pulmonary disease 63 (6.3%) 76 (7.7%) 0.05133
Cerebrovascular accident 43 (4.3%) 53 (5.3%) 0.04697
Dementia 11 (1.1%) 13 (1.3%) 0.01843
High blood pressure 585 (58.9%) 584 (58.8%) 0.00205
Heart failure 31 (3.1%) 30 (3.0%) 0.00584
Kidney disease 155 (15.6%) 161 (16.2%) 0.01652
Liver disease 14 (1.4%) 14 (1.4%) 0.00000
Peripheral vascular disease 24 (2.4%) 26 (2.6%) 0.01286
Dyslipidaemia 1 (0.1%) 2 (0.2%) 0.02593
Foot complications 6 (0.6%) 7 (0.7%) 0.01249
Neuropathy 12 (1.2%) 10 (1.0%) 0.01924
Retinopathy 141 (14.2%) 153 (15.4%) 0.03403
Other vascular complications 74 (7.5%) 71 (7.2%) 0.01161
Ethnicity 0.02407
Black 17 (1.7%) 16 (1.6%)
South-east Asian 30 (3.0%) 32 (3.2%)
White 343 (34.5%) 348 (35.0%)
Other 15 (1.5%) 13 (1.3%)
Missing 588 (59.2%) 584 (58.8%)
Smoking status 0.03440
Non-smoker 469 (47.2%) 454 (45.7%)
Ex-smoker 368 (37.1%) 384 (38.7%)
Smoker 156 (15.7%) 155 (15.6%)
Alcohol assumption 0.02871
No 153 (15.4%) 146 (14.7%)
(Continues)